Oblique Therapeutics

Oblique Therapeutics is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Oblique Therapeutics. Oblique Therapeutics is a privately held Swedish biotech, developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. We use Abiprot, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs – two antibody candidates: aKRAS in advanced cancer, aTRPV1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, we have two antibodies in collaboration with a large pharma company. We make medicines that matter to patients.